University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC)
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Glaspy, John A
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
NCT00039247: Darbepoetin Alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy

Active, not recruiting
2
NA
darbepoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT04712851: Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Recruiting
2
25
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
01/25
01/26
Glaspy BMS CA209-9ET Breast, NCT04185311: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated
1
6
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/23
05/23
NCT00090935: Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy

Active, not recruiting
N/A
US
epoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
 
 

Download Options